Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2014

Open Access 01-12-2014 | Review

Tissue factor in tumor microenvironment: a systematic review

Authors: Xiao Han, Bo Guo, Yongsheng Li, Bo Zhu

Published in: Journal of Hematology & Oncology | Issue 1/2014

Login to get access

Abstract

The aberrant hemostasis is a common manifestation of cancer, and venous thromboembolism (VTE) is the second leading cause of cancer patients’ mortality. Tissue factor (TF), comprising of a 47-kDa transmembrane protein that presents in subendothelial tissues and leukocytes and a soluble isoform, have distinct roles in the initiation of extrinsic coagulation cascade and thrombosis. Laboratory and clinical evidence showed the deviant expression of TF in several cancer systems and its tumor-promoting effects. TF contributes to myeloid cell recruitment in tumor stroma, thereby remodeling of tumor microenvironment. Additionally, the number of TF-positive-microparticles (TF+MP) from tumor origins correlates with the VTE rates in cancer patients. In this review, we summarize our current understanding of the TF regulation and roles in tumor progression and clinical complications.
Appendix
Available only for authorised users
Literature
1.
Spicer EK, Horton R, Bloem L, Bach R, Williams KR, Guha A, Kraus J, Lin TC, Nemerson Y, Konigsberg WH: Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci U S A. 1987, 84: 5148-5152. 10.1073/pnas.84.15.5148.PubMedCentralCrossRefPubMed
2.
Versteeg HH, Peppelenbosch MP, Spek CA: The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling?. Thromb Haemost. 2001, 86: 1353-1359.PubMed
3.
Tardos JG, Eisenreich A, Deikus G, Bechhofer DH, Chandradas S, Zafar U, Rauch U, Bogdanov VY: SR proteins ASF/SF2 and SRp55 participate in tissue factor biosynthesis in human monocytic cells. J Thromb Haemost. 2008, 6: 877-884. 10.1111/j.1538-7836.2008.02946.x.CrossRefPubMed
4.
Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y: Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003, 9: 458-462. 10.1038/nm841.CrossRefPubMed
5.
Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U: Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res. 2005, 96: 1233-1239. 10.1161/01.RES.0000171805.24799.fa.CrossRefPubMed
6.
Eisenreich A, Bogdanov VY, Zakrzewicz A, Pries A, Antoniak S, Poller W, Schultheiss HP, Rauch U: Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ Res. 2009, 104: 589-599. 10.1161/CIRCRESAHA.108.183905.CrossRefPubMed
7.
Censarek P, Bobbe A, Grandoch M, Schror K, Weber AA: Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb Haemost. 2007, 97: 11-14.PubMed
8.
Srinivasan R, Bogdanov VY: Alternatively spliced tissue factor: discovery, insights, clinical implications. Front Biosci. 2011, 16: 3061-3071. 10.2741/3899.CrossRef
9.
10.
Yu YJ, Li YM, Hou XD, Guo C, Cao N, Jiao ZY: Effect of tissue factor on invasion inhibition and apoptosis inducing effect of oxaliplatin in human gastric cancer cell. Asian Pac J Cancer Prev. 2012, 13: 1845-1849. 10.7314/APJCP.2012.13.5.1845.CrossRefPubMed
11.
Eisenreich A, Boltzen U, Malz R, Schultheiss HP, Rauch U: Overexpression of alternatively spliced tissue factor induces the pro-angiogenic properties of murine cardiomyocytic HL-1 cells. Circ J. 2011, 75: 1235-1242. 10.1253/circj.CJ-10-0783.CrossRefPubMed
12.
Kocaturk B, Van den Berg YW, Tieken C, Mieog JS, de Kruijf EM, Engels CC, van der Ent MA, Kuppen PJ, Van de Velde CJ, Ruf W, Reitsma PH, Osanto S, Liefers GJ, Bogdanov VY, Versteeg HH: Alternatively spliced tissue factor promotes breast cancer growth in a beta1 integrin-dependent manner. Proc Natl Acad Sci U S A. 2013, 110: 11517-11522. 10.1073/pnas.1307100110.PubMedCentralCrossRefPubMed
13.
Liu Y, Jiang P, Capkova K, Xue D, Ye L, Sinha SC, Mackman N, Janda KD, Liu C: Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res. 2011, 71: 6492-6502. 10.1158/0008-5472.CAN-11-1145.CrossRefPubMed
14.
Saito Y, Hashimoto Y, Kuroda J, Yasunaga M, Koga Y, Takahashi A, Matsumura Y: The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody. Eur J Cancer. 2011, 47: 2230-2239. 10.1016/j.ejca.2011.04.028.CrossRefPubMed
15.
Schaffner F, Yokota N, Ruf W: Tissue factor proangiogenic signaling in cancer progression. Thromb Res. 2012, 129 (Suppl 1): S127-S131. 10.1016/S0049-3848(12)70032-4.CrossRefPubMed
16.
Welsh J, Smith JD, Yates KR, Greenman J, Maraveyas A, Madden LA: Tissue factor expression determines tumour cell coagulation kinetics. Int J Lab Hematol. 2012, 34: 396-402. 10.1111/j.1751-553X.2012.01409.x.CrossRefPubMed
17.
Hong H, Zhang Y, Nayak TR, Engle JW, Wong HC, Liu B, Barnhart TE, Cai W: Immuno-PET of tissue factor in pancreatic cancer. J Nucl Med. 2012, 53: 1748-1754. 10.2967/jnumed.112.105460.PubMedCentralCrossRefPubMed
18.
Cocco E, Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, Todeschini P, Carrara L, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Lockwood CJ, Santin AD: Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC Cancer. 2011, 11: 263-10.1186/1471-2407-11-263.PubMedCentralCrossRefPubMed
19.
20.
21.
Castellana D, Toti F, Freyssinet JM: Membrane microvesicles: macromessengers in cancer disease and progression. Thromb Res. 2010, 125 (Suppl 2): S84-S88. 10.1016/S0049-3848(10)70021-9.CrossRefPubMed
22.
Pabinger I, Thaler J, Ay C: Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013, 122: 2011-2018. 10.1182/blood-2013-04-460147.CrossRefPubMed
23.
Bharthuar A, Khorana AA, Hutson A, Wang JG, Key NS, Mackman N, Iyer RV: Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res. 2013, 132: 180-184. 10.1016/j.thromres.2013.06.026.CrossRefPubMed
24.
Ma Z, Zhang T, Wang R, Cheng Z, Xu H, Li W, Wang Y, Wang X: Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism. Int J Gynecol Cancer. 2011, 21: 616-624. 10.1097/IGC.0b013e3182150e98.CrossRefPubMed
25.
26.
27.
Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A, Mullauer L, Gnant M, Scheithauer W, Pabinger I: Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest. 2013, 43: 277-285. 10.1111/eci.12042.CrossRefPubMed
28.
Yamashita H, Kitayama J, Ishikawa M, Nagawa H: Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol. 2007, 95: 324-331. 10.1002/jso.20680.CrossRefPubMed
29.
Lwaleed BA, Lam L, Lasebai M, Cooper AJ: Expression of tissue factor and tissue factor pathway inhibitor in microparticles and subcellular fractions of normal and malignant prostate cell lines. Blood Coagul Fibrinolysis. 2013, 24: 339-343. 10.1097/MBC.0b013e32835e98a6.CrossRefPubMed
30.
Li H, Tian ML, Yu G, Liu YC, Wang X, Zhang J, Ji SQ, Zhu J, Wan YL, Tang JQ: Hyperthermia synergizes with tissue factor knockdown to suppress the growth and hepatic metastasis of colorectal cancer in orthotopic tumor model. J Surg Oncol. 2012, 106: 689-695. 10.1002/jso.23136.CrossRefPubMed
31.
Eisenreich A, Zakrzewicz A, Huber K, Thierbach H, Pepke W, Goldin-Lang P, Schultheiss HP, Pries A, Rauch U: Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. Oncol Rep. 2013, 30: 462-470.PubMed
32.
Zhao Y, Zhang D, Wang S, Tao L, Wang A, Chen W, Zhu Z, Zheng S, Gao X, Lu Y: Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-kappaB/tissue factor/Factor Xa pathway in melanoma B16F10 cells. PLoS One. 2013, 8: e56557-10.1371/journal.pone.0056557.PubMedCentralCrossRefPubMed
33.
Yu JL, Rak JW: Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost. 2004, 2: 2065-2067. 10.1111/j.1538-7836.2004.00972.x.CrossRefPubMed
34.
Contrino J, Hair G, Kreutzer DL, Rickles FR: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996, 2: 209-215. 10.1038/nm0296-209.CrossRefPubMed
35.
Vrana JA, Stang MT, Grande JP, Getz MJ: Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res. 1996, 56: 5063-5070.PubMed
36.
van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, Spek CA, Reitsma PH, Bogdanov VY, Versteeg HH: Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A. 2009, 106: 19497-19502. 10.1073/pnas.0905325106.PubMedCentralCrossRefPubMed
37.
Godby RC, Van Den Berg YW, Srinivasan R, Sturm R, Hui DY, Konieczny SF, Aronow BJ, Ozhegov E, Ruf W, Versteeg HH, Bogdanov VY: Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrin-mediated signaling in murine models. Mol Med. 2012, 18: 771-779. 10.2119/molmed.2011.00416.PubMedCentralCrossRefPubMed
38.
39.
Rautou PE, Mackman N: Microvesicles as risk markers for venous thrombosis. Expert Rev Hematol. 2013, 6: 91-101. 10.1586/ehm.12.74.CrossRefPubMed
40.
Rao B, Gao Y, Huang J, Gao X, Fu X, Huang M, Yao J, Wang J, Li W, Zhang J, Liu H, Wang L: Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis. Int J Colorectal Dis. 2011, 26: 593-601. 10.1007/s00384-011-1164-1.CrossRefPubMed
41.
Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005, 105: 1734-1741. 10.1182/blood-2004-05-2042.CrossRefPubMed
42.
Magnus N, Garnier D, Rak J: Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood. 2010, 116: 815-818. 10.1182/blood-2009-10-250639.CrossRefPubMed
43.
Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ: Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009, 69: 2540-2549. 10.1158/0008-5472.CAN-08-1547.PubMedCentralCrossRefPubMed
44.
Eisenreich A, Malz R, Pepke W, Ayral Y, Poller W, Schultheiss HP, Rauch U: Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells. Circ J. 2009, 73: 1746-1752. 10.1253/circj.CJ-99-0225.CrossRefPubMed
45.
Provencal M, Labbe D, Veitch R, Boivin D, Rivard GE, Sartelet H, Robitaille Y, Gingras D, Beliveau R: c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. Carcinogenesis. 2009, 30: 1089-1096. 10.1093/carcin/bgp085.CrossRefPubMed
46.
Vieira KB, Goldstein DJ, Villa LL: Tumor necrosis factor alpha interferes with the cell cycle of normal and papillomavirus-immortalized human keratinocytes. Cancer Res. 1996, 56: 2452-2457.PubMed
47.
Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med. 2004, 10: 789-799. 10.1038/nm1087.CrossRefPubMed
48.
Lee BJ, Kim JH, Woo SH, Kim JH, Kim DH, Yu YS: Tissue factor is involved in retinoblastoma cell proliferation via both the Akt and extracellular signal-regulated kinase pathways. Oncol Rep. 2011, 26: 665-670.PubMed
49.
Sun L, Liu Y, Lin S, Shang J, Liu J, Li J, Yuan S, Zhang L: Early growth response gene-1 and hypoxia-inducible factor-1alpha affect tumor metastasis via regulation of tissue factor. Acta Oncol. 2013, 52: 842-851. 10.3109/0284186X.2013.705890.CrossRefPubMed
50.
Bastarache JA, Sebag SC, Grove BS, Ware LB: Interferon-gamma and tumor necrosis factor-alpha act synergistically to up-regulate tissue factor in alveolar epithelial cells. Exp Lung Res. 2011, 37: 509-517. 10.3109/01902148.2011.605512.PubMedCentralCrossRefPubMed
51.
Wygrecka M, Zakrzewicz D, Taborski B, Didiasova M, Kwapiszewska G, Preissner KT, Markart P: TGF-beta1 induces tissue factor expression in human lung fibroblasts in a PI3K/JNK/Akt-dependent and AP-1-dependent manner. Am J Respir Cell Mol Biol. 2012, 47: 614-627. 10.1165/rcmb.2012-0097OC.CrossRefPubMed
52.
Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, Szklarczyk D, Jensen LJ, Fabbro D, Trappe J, Rauch U, Bracher F, Knapp S: Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011, 18: 67-76. 10.1016/j.chembiol.2010.11.009.PubMedCentralCrossRefPubMed
53.
54.
Eisenreich A, Leppert U: The impact of microRNAs on the regulation of tissue factor biology. Trends Cardiovasc Med. 2014, 24: 128-132. 10.1016/j.tcm.2013.09.005.CrossRefPubMed
55.
A E, Rauch U: Regulation of the tissue factor isoform expression and thrombogenicity of HMEC-1 by miR-126 and miR-19a. Cell Biol: Res Ther. 2013, 2: 1-doi:10.4172/2324-9293.1000101
56.
Yu G, Li H, Wang X, Wu T, Zhu J, Huang S, Wan Y, Tang J: MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion. Mol Cell Biochem. 2013, 380: 239-247. 10.1007/s11010-013-1679-6.CrossRefPubMed
57.
Teruel R, Perez-Sanchez C, Corral J, Herranz MT, Perez-Andreu V, Saiz E, Garcia-Barbera N, Martinez-Martinez I, Roldan V, Vicente V, Lopez-Pedrera C, Martinez C: Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost. 2011, 9: 1985-1992. 10.1111/j.1538-7836.2011.04451.x.CrossRefPubMed
58.
Garnier D, Magnus N, D’Asti E, Hashemi M, Meehan B, Milsom C, Rak J: Genetic pathways linking hemostasis and cancer. Thromb Res. 2012, 129 (Suppl 1): S22-S29. 10.1016/S0049-3848(12)70012-9.CrossRefPubMed
59.
Leppert U, Eisenreich A: The role of tissue factor isoforms in cancer biology.Int J Cancer 2014, doi:10.1002/ijc.28959.
60.
van den Berg YW, Osanto S, Reitsma PH, Versteeg HH: The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012, 119: 924-932. 10.1182/blood-2011-06-317685.CrossRefPubMed
61.
Wu B, Zhou H, Hu L, Mu Y, Wu Y: Involvement of PKCalpha activation in TF/VIIa/PAR2-induced proliferation, migration, and survival of colon cancer cell SW620. Tumour Biol. 2013, 34: 837-846. 10.1007/s13277-012-0614-x.CrossRefPubMed
62.
Hu L, Xia L, Zhou H, Wu B, Mu Y, Wu Y, Yan J: TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCalpha and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620. Tumour Biol. 2013, 34: 2573-2581. 10.1007/s13277-013-0803-2.CrossRefPubMed
63.
Aberg M, Johnell M, Wickstrom M, Siegbahn A: Tissue Factor/FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1). Thromb Res. 2011, 127: 141-148. 10.1016/j.thromres.2010.11.015.CrossRefPubMed
64.
Signaevsky M, Hobbs J, Doll J, Liu N, Soff GA: Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis. Semin Thromb Hemost. 2008, 34: 161-169. 10.1055/s-2008-1079256.CrossRefPubMed
65.
Hobbs JE, Zakarija A, Cundiff DL, Doll JA, Hymen E, Cornwell M, Crawford SE, Liu N, Signaevsky M, Soff GA: Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res. 2007, 120 (Suppl 2): S13-S21. 10.1016/S0049-3848(07)70126-3.CrossRefPubMed
66.
Maeda S, Maeda S, Ohno K, Kaji N, Hori M, Fujino Y, Tsujimoto H: Protease-activated receptor-2 induces proinflammatory cytokine and chemokine gene expression in canine keratinocytes. Vet Immunol Immunopathol. 2013, 153: 17-25. 10.1016/j.vetimm.2013.01.018.CrossRefPubMed
67.
Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W: Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell. 2004, 15: 4416-4425. 10.1091/mbc.E03-09-0640.PubMedCentralCrossRefPubMed
68.
Ott I, Weigand B, Michl R, Seitz I, Sabbari-Erfani N, Neumann FJ, Schomig A: Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation. 2005, 111: 349-355. 10.1161/01.CIR.0000153333.52294.42.CrossRefPubMed
69.
Muller M, Albrecht S, Golfert F, Hofer A, Funk RH, Magdolen V, Flossel C, Luther T: Localization of tissue factor in actin-filament-rich membrane areas of epithelial cells. Exp Cell Res. 1999, 248: 136-147. 10.1006/excr.1999.4395.CrossRefPubMed
70.
Palumbo JS: Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost. 2008, 34: 154-160. 10.1055/s-2008-1079255.CrossRefPubMed
71.
Ruf W, Mueller BM: Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost. 2006, 32 (Suppl 1): 61-68. 10.1055/s-2006-939555.CrossRefPubMed
72.
Degen JL, Palumbo JS: Hemostatic factors, innate immunity and malignancy. Thromb Res. 2012, 129 (Suppl 1): S1-S5. 10.1016/S0049-3848(12)70143-3.CrossRefPubMed
73.
Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, Kombrinck KW, Talmage KE, Souri M, Ichinose A, Degen JL: Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost. 2008, 6: 812-819. 10.1111/j.1538-7836.2008.02938.x.CrossRefPubMed
74.
Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL: Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost. 2002, 87: 930-936.PubMed
75.
Gil-Bernabe AM, Ferjancic S, Tlalka M, Zhao L, Allen PD, Im JH, Watson K, Hill SA, Amirkhosravi A, Francis JL, Pollard JW, Ruf W, Muschel RJ: Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood. 2012, 119: 3164-3175. 10.1182/blood-2011-08-376426.CrossRefPubMed
76.
Ma S: Biology and clinical implications of CD133(+) liver cancer stem cells. Exp Cell Res. 2013, 319: 126-132. 10.1016/j.yexcr.2012.09.007.CrossRefPubMed
77.
Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS: Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011, 71: 614-624. 10.1158/0008-5472.CAN-10-0538.PubMedCentralCrossRefPubMed
78.
Long H, Xie R, Xiang T, Zhao Z, Lin S, Liang Z, Chen Z, Zhu B: Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells. 2012, 30: 2309-2319. 10.1002/stem.1194.CrossRefPubMed
79.
Milsom CC, Yu JL, Mackman N, Micallef J, Anderson GM, Guha A, Rak JW: Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res. 2008, 68: 10068-10076. 10.1158/0008-5472.CAN-08-2067.PubMedCentralCrossRefPubMed
80.
Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M: Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity. 2013, 38: 541-554. 10.1016/j.immuni.2013.02.007.CrossRefPubMed
81.
Krisinger MJ, Goebeler V, Lu Z, Meixner SC, Myles T, Pryzdial EL, Conway EM: Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood. 2012, 120: 1717-1725. 10.1182/blood-2012-02-412080.CrossRefPubMed
82.
Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD: Modulation of the antitumor immune response by complement. Nat Immunol. 2008, 9: 1225-1235. 10.1038/ni.1655.PubMedCentralCrossRefPubMed
83.
Ferjancic S, Gil-Bernabe AM, Hill SA, Allen PD, Richardson P, Sparey T, Savory E, McGuffog J, Muschel RJ: VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice. Blood. 2013, 121: 3289-3297. 10.1182/blood-2012-08-449819.CrossRefPubMed
84.
Falanga A, Russo L: Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie. 2012, 32: 115-125. 10.5482/ha-1170.CrossRefPubMed
85.
Lazo-Langner A, Goss GD, Spaans JN, Rodger MA: The effect of low-molecular-weight heparin on cancer survival: a systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2007, 5: 729-737. 10.1111/j.1538-7836.2007.02427.x.CrossRefPubMed
86.
Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005, 23: 2130-2135. 10.1200/JCO.2005.03.134.CrossRefPubMed
87.
Hull RD, Townshend G: Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence. Thromb Haemost. 2013, 110: 14-22. 10.1160/TH12-12-0931.CrossRefPubMed
88.
Morel O, Jesel L, Freyssinet JM, Toti F: Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011, 31: 15-26. 10.1161/ATVBAHA.109.200956.CrossRefPubMed
89.
Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle PA, Weltermann A: Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 2007, 97: 119-123.PubMed
90.
Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, Lopez JA: Microvesicle-associated tissue factor and Trousseau’s syndrome. J Thromb Haemost. 2007, 5: 70-74. 10.1111/j.1538-7836.2006.02301.x.PubMedCentralCrossRefPubMed
91.
Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S: Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost. 2007, 5: 520-527. 10.1111/j.1538-7836.2007.02369.x.CrossRefPubMed
92.
Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S: Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost. 2009, 7: 1421-1423. 10.1111/j.1538-7836.2009.03504.x.CrossRefPubMed
93.
Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B: Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009, 15: 6830-6840. 10.1158/1078-0432.CCR-09-0371.PubMedCentralCrossRefPubMed
Metadata
Title
Tissue factor in tumor microenvironment: a systematic review
Authors
Xiao Han
Bo Guo
Yongsheng Li
Bo Zhu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2014
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-014-0054-8

Other articles of this Issue 1/2014

Journal of Hematology & Oncology 1/2014 Go to the issue

Review

New antibody approaches to lymphoma therapy

Research

Identification of nuclear-enriched miRNAs during mouse granulopoiesis

Research

Homeobox gene expression in acute myeloid leukemia is linked to typical underlying molecular aberrations

Research

Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression

Review

Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells

Research

Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits